SCHEMBL4624243

SCHEMBL4624243

C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C1CC1)C(=O)CO

nearest known ligand 0.80

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 18/20 0.80
▸ MMP1 P03956 16/20 0.80
▸ PGR P06401 4/20 0.79
▸ CYP3A4 P08684 2/20 0.79
▸ MEN1 O00255 1/20 0.79
▸ USP2 O75604 1/20 0.79
▸ KMT2A Q03164 1/20 0.79
▸ MLNR O43193 1/20 0.73
▸ NR1I2 O75469 1/20 0.73
▸ ABCB11 O95342 1/20 0.73
▸ LMNA P02545 1/20 0.73
▸ MAPT P10636 1/20 0.73
▸ CYP3A5 P20815 1/20 0.73
▸ PPARG P37231 1/20 0.73
▸ SMN1; SMN2 Q16637 1/20 0.73
▸ NPSR1 Q6W5P4 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4624240 1.00 NR3C1 (0.80) NR3C1MMP1PGRCYP3A4MEN1
SCHEMBL4624245 1.00 NR3C1 (0.80) NR3C1MMP1PGRCYP3A4MEN1
SCHEMBL9159208 0.93 NR3C1 (0.85) NR3C1MMP1PGRCYP3A4MEN1
SCHEMBL9159212 0.93 NR3C1 (0.85) NR3C1MMP1PGRCYP3A4MEN1
SCHEMBL7547 0.93 NR3C1 (0.83) NR3C1MMP1PGRCYP3A4MEN1
SCHEMBL6986508 0.93 NR3C1 (0.83) NR3C1MMP1PGRCYP3A4MEN1
SCHEMBL11812693 0.93 NR3C1 (0.83) NR3C1MMP1PGRCYP3A4MEN1
SCHEMBL9160605 0.92 NR3C1 (0.83) NR3C1MMP1PGRCYP3A4MEN1
SCHEMBL25372269 0.92 NR3C1 (0.87) NR3C1MMP1PGRCYP3A4MEN1
SCHEMBL9768478 0.92 NR3C1 (0.87) NR3C1MMP1PGRCYP3A4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1344526-B1 PREVENTIVES/REMEDIES FOR INFLAMMATORY AIRWAY DISEASES NIPPON SHINYAKU CO LTD (JP) 2008-05-28 — — EP claimed
US-7214672-B2 Preventives/remedies for inflammatory airway diseases NIPPON SHINYAKU CO., LTD. (JP) 2007-05-08 — — US claimed
US-20040053904-A1 Preventive/ermedies for inflammatory airway diseases NIPPON SHINYAKU CO., LTD. (JP) 2004-03-18 — — US claimed
EP-1344526-A1 PREVENTIVES/ERMEDIES FOR INFLAMMATORY AIRWAY DISEASES SSP Co., Ltd. (JP) 2003-09-17 — — EP claimed
US-20050163724-A1 Powdery respiratory tonic composition SSP CO., LTD. (JP) 2005-07-28 — — US disclosed
EP-1514549-A1 POWDERY RESPIRATORY TONIC COMPOSITION SSP Co., Ltd. (JP) 2005-03-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053904-A1 Preventive/ermedies for inflammatory airway diseases NR3C1, OXER1, NR5A1 NR3C1 1/4885MMP1 234/4885PGR 1911/4885
US-20050163724-A1 Powdery respiratory tonic composition IL5, IL17A, RORC NR3C1 12/4885MMP1 153/4885PGR 1432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback